Drug Profile
SAR 228810
Alternative Names: Anti-protofibrillar AB mAb; SAR228810Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Sanofi
- Class Antidementias; Monoclonal antibodies
- Mechanism of Action Amyloid inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 31 Dec 2018 Discontinued - Phase-I for Alzheimer's disease in Sweden (IV) before December 2019 (Sanofi pipeline, February 2019)
- 31 Dec 2018 Discontinued - Phase-I for Alzheimer's disease in Sweden (SC) before December 2019 (Sanofi pipeline, February 2019)
- 31 Jul 2018 sanofi announces intention to submit regulatory application for Alzheimer’s disease in 2022